Controller / Accountant (m/f/d)

Your mission

• Run day‑to‑day accounting for our German HQ and newly‑launched US subsidiary, ensuring clean ledgers and stellar month‑end closes.
• Consolidate multi‑entity financials (HGB + IFRS/US‑GAAP) and prepare management reports that land with non‑finance stakeholders.
• Build scalable processes—from expense policy to ERP workflows—that keep pace with 2× YoY headcount.
• Own external relationships with tax advisers, auditors, banks, and payroll providers on both sides of the Atlantic.
• Partner with the Head of Finance on budgets, rolling forecasts, scenario modelling, and board decks—becoming the in‑house modelling co‑pilot for new product lines and fundraising.
• Level‑up our data stack by championing automation and dashboarding (Excel, Sheets, or the tools you love) so insights are always a click away.

Your profile

• 1‑5 years in audit, controlling, or accounting (start‑up scale‑ups or Big‑4 welcome).
• Working knowledge of German GAAP (HGB) plus either IFRS or US‑GAAP; experience consolidating multiple entities & currencies.
• Confident with month‑end close, P&L, BS, and cash‑flow statements.
• Fluency in German (C1/C2) and English (written and spoken) is a must. Comfortable collaborating across time zones.
• Flexible, generalist mentality - you are adaptable and willing to handle a broad range of tasks, even outside of core accounting, to support the team's needs.
• Detail‑obsessed but pragmatic—able to set 80/20 processes that unblock the team and ship.
• Valid work visa.

About Us
*At CPTx, we are pioneering single-stranded DNA technology and manufacturing processes to engineer advanced therapies faster and more reliably than ever before.

Founded in 2021 in Munich, Germany, and now also with offices in South San Francisco, California, we set out to translate more than 15 years of foundational research at the Technical University of Munich into novel therapeutics. Merging science and engineering, we leverage programmable DNA-based fabrication technologies to create novel multi-modal drugs that include targetable delivery functionalities.

Our leadership team includes high profile academic and industry experts, enabling us to address disease challenges across genetic, infectious, and autoimmune diseases fields.
*